|
GB202103372D0
|
|
Modified clostridial neurotoxins
|
|
GB202100566D0
|
|
Treatment of brain damage
|
|
GB202015618D0
|
|
Method for producing beta-trypsin
|
|
GB202010934D0
|
|
Controlling operation of a bioreactor vessel
|
|
GB202003867D0
|
|
Treatment of limbl spasticity
|
|
GB202003803D0
|
|
Treatment of limb spasticity
|
|
GB202003813D0
|
|
Treatment of upper facial lines
|
|
GB202001353D0
|
|
Treatment of skin conditions
|
|
WO2020115490A1
|
|
Treatment of symptoms of traumatic brain injury
|
|
WO2020109761A1
|
|
Dosing calculator for spasticity
|
|
GB201914034D0
|
|
Treatment of neurological disorders
|
|
AU2019348732A1
|
|
Clostridial neurotoxins comprising an exogenous activation loop
|
|
CA3111674A1
|
|
Cell-based clostridal neurotoxin assays
|
|
WO2019243376A1
|
|
Intramuscular injection of botulinum toxin for the treatment of vulvodynia
|
|
EP3796929A1
|
|
Suppression of bone cancer-induced allodynia
|
|
GB201907016D0
|
|
Screening method to determine suitability for participation in a clinical trial
|
|
WO2019162696A1
|
|
Use of ultrasound to guide injection of non-cytotoxic protease
|
|
EP3746463A1
|
|
Non-neuronal snare-cleaving botulinum neurotoxins
|
|
GB201900633D0
|
|
Compositions and methods for treating, preventing or ameliorating pain
|
|
GB201900621D0
|
|
Labelled polypeptides
|
